Logo image of BRDS

BIRD GLOBAL INC-CLASS A (BRDS) Stock Fundamental Analysis

NYSE:BRDS - New York Stock Exchange, Inc. - US09077J2069 - Common Stock - Currency: USD

0.9  -0.01 (-1.52%)

Fundamental Rating

1

Taking everything into account, BRDS scores 1 out of 10 in our fundamental rating. BRDS was compared to 41 industry peers in the Ground Transportation industry. Both the profitability and financial health of BRDS have multiple concerns. BRDS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BRDS has reported negative net income.
BRDS had a negative operating cash flow in the past year.
BRDS Yearly Net Income VS EBIT VS OCF VS FCFBRDS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -100M -200M -300M

1.2 Ratios

BRDS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRDS Yearly ROA, ROE, ROICBRDS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -500 -1K

1.3 Margins

BRDS has a Gross Margin (37.01%) which is in line with its industry peers.
BRDS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRDS Yearly Profit, Operating, Gross MarginsBRDS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -50 -100 -150 -200 -250

More info and screens

0

2. Health

2.1 Basic Checks

BRDS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BRDS has more shares outstanding
BRDS has a worse debt/assets ratio than last year.
BRDS Yearly Shares OutstandingBRDS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 50M 100M 150M 200M 250M
BRDS Yearly Total Debt VS Total AssetsBRDS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

BRDS has an Altman-Z score of -12.27. This is a bad value and indicates that BRDS is not financially healthy and even has some risk of bankruptcy.
BRDS has a worse Altman-Z score (-12.27) than 92.31% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.27
ROIC/WACCN/A
WACC9.84%
BRDS Yearly LT Debt VS Equity VS FCFBRDS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 200M -200M

2.3 Liquidity

BRDS has a Current Ratio of 0.21. This is a bad value and indicates that BRDS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.21, BRDS is doing worse than 87.18% of the companies in the same industry.
A Quick Ratio of 0.19 indicates that BRDS may have some problems paying its short term obligations.
BRDS has a Quick ratio of 0.19. This is amonst the worse of the industry: BRDS underperforms 87.18% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.19
BRDS Yearly Current Assets VS Current LiabilitesBRDS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for BRDS have decreased strongly by -441.18% in the last year.
The Revenue for BRDS has decreased by -11.19% in the past year. This is quite bad
The Revenue has been growing by 17.58% on average over the past years. This is quite good.
EPS 1Y (TTM)-441.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.57%
Revenue 1Y (TTM)-11.19%
Revenue growth 3Y17.58%
Revenue growth 5YN/A
Sales Q2Q%-52.68%

3.2 Future

BRDS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -20.92% yearly.
BRDS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.96% yearly.
EPS Next Y-52.06%
EPS Next 2Y-20.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.26%
Revenue Next 2Y9.96%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BRDS Yearly Revenue VS EstimatesBRDS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 100M 200M 300M
BRDS Yearly EPS VS EstimatesBRDS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BRDS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BRDS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRDS Price Earnings VS Forward Price EarningsBRDS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BRDS Per share dataBRDS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as BRDS's earnings are expected to decrease with -20.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.92%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BRDS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIRD GLOBAL INC-CLASS A

NYSE:BRDS (9/22/2023, 8:04:01 PM)

0.9

-0.01 (-1.52%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)08-09 2023-08-09/amc
Earnings (Next)11-13 2023-11-13/amc
Inst Owners1.58%
Inst Owner Change0%
Ins Owners426.5%
Ins Owner Change0%
Market Cap11.64M
Analysts43.33
Price Target331.5 (36733.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.41%
Min EPS beat(2)-71.57%
Max EPS beat(2)42.75%
EPS beat(4)2
Avg EPS beat(4)2.98%
Min EPS beat(4)-71.57%
Max EPS beat(4)73.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-42.7%
Min Revenue beat(2)-54.36%
Max Revenue beat(2)-31.04%
Revenue beat(4)1
Avg Revenue beat(4)-21.17%
Min Revenue beat(4)-54.36%
Max Revenue beat(4)27.95%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)94.03%
PT rev (3m)94.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2400%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.05
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.28
EYN/A
EPS(NY)-6.37
Fwd EYN/A
FCF(TTM)-3.3
FCFYN/A
OCF(TTM)-2.57
OCFYN/A
SpS17.04
BVpS-0.84
TBVpS-3.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.01%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.41%
Cap/Sales 4.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.19
Altman-Z -12.27
F-Score3
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)200.34%
Cap/Depr(5y)N/A
Cap/Sales(3y)54.49%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-441.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.57%
EPS Next Y-52.06%
EPS Next 2Y-20.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.19%
Revenue growth 3Y17.58%
Revenue growth 5YN/A
Sales Q2Q%-52.68%
Revenue Next Year4.26%
Revenue Next 2Y9.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y81.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year112.36%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.82%
OCF growth 3YN/A
OCF growth 5YN/A